title: Initial and long-term outcomes of sirolimus-eluting stents for calcified lesions compared with bare-metal stents.
abstract: The aim of this study was to compare the initial and long-term outcomes of sirolimus-eluting stents (SES) and bare-metal stents (BMS) in patients with calcified lesions without performing rotational atherectomy. The subjects were 79 consecutive lesions (38 in the SES group and 41 in the BMS group) which were confirmed to have superficially calcified lesions by intravascular ultrasound. In all lesions, the stent was implanted after predilatation with a balloon. The patient characteristics were not different between the 2 groups. All procedures were successfully performed in both groups. Vessel area was significantly smaller in the SES group than in the BMS group (11.01 +/- 3.88 mm(2) versus 13.08 +/- 3.49 mm(2), P < 0.005), as was the lumen area (5.41 +/- 2.31mm(2) versus 6.48 +/- 2.04 mm(2), P < 0.005). Minimum stent area was significantly smaller in the SES group than in the BMS group (5.61 +/- 1.54 mm(2) versus 6.69 +/- 1.74 mm(2), P < 0.01). In cases in whom angiographic follow-ups were performed, the late loss was significantly smaller in the SES group than in the BMS group (0.19 +/- 0.49 mm versus 0.76 +/- 0.48 mm, P < 0.001). The restenosis rate was significantly lower in the SES group than in the BMS group (8.8% versus 33.3%, P < 0.05) and the TLR rate tended to be lower in the SES group (7.9% versus 19.5%). Stent thrombosis was not observed in either group. The results suggest that SES are more effective than BMS and can be used safely when treating calcified lesions if predilatation with a balloon is possible.
authors.affiliation: Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, Daisan Hospital, Komae-shi, Tokyo, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Seo
authors.forename: Takuro
authors.initials: T
authors.lastname: Fujii
authors.forename: Terumasa
authors.initials: T
authors.lastname: Inoue
authors.forename: Satoru
authors.initials: S
authors.lastname: Onoda
authors.forename: Atsushi
authors.initials: A
authors.lastname: Koga
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Keiichi
authors.initials: K
authors.lastname: Chin
authors.forename: Takashi
authors.initials: T
authors.lastname: Kurusu
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Takikawa
authors.forename: Takahiro
authors.initials: T
authors.lastname: Shibata
authors.forename: Masayuki
authors.initials: M
authors.lastname: Taniguchi
authors.forename: Seibu
authors.initials: S
authors.lastname: Mochizuki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D002114:Calcinosis / Q000000981:diagnostic imaging / Q000628:therapy*; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D004867:Equipment Design; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011859:Radiography; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus